Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): A case series.
作者信息
Andarawewa S, Aygören-Pürsün E
机构信息
Hereditary Angioedema Center, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt, Germany.
出版信息
Front Allergy. 2022 Aug 12;3:949387. doi: 10.3389/falgy.2022.949387. eCollection 2022.
Abstract
摘要
相似文献
1
Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): A case series.遗传性血管性水肿（HAE-C1-INH）患者长期治疗的个体化方法：病例系列
Front Allergy. 2022 Aug 12;3:949387. doi: 10.3389/falgy.2022.949387. eCollection 2022.
2
Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema-A Long-Term Survey.遗传性血管性水肿儿童和青少年血浆源性C1抑制剂治疗的临床特征与安全性——一项长期调查
J Allergy Clin Immunol Pract. 2020 Jul-Aug;8(7):2379-2383. doi: 10.1016/j.jaip.2020.02.043. Epub 2020 Mar 17.
3
Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema.遗传性血管性水肿急性和预防性治疗中 C1 酯酶抑制剂替代疗法的最新进展。
Clin Rev Allergy Immunol. 2019 Apr;56(2):207-218. doi: 10.1007/s12016-018-8684-1.
4
C1 Inhibitor Activity and Angioedema Attacks in Patients with Hereditary Angioedema.遗传性血管性水肿患者的C1抑制剂活性与血管性水肿发作
J Allergy Clin Immunol Pract. 2020 Mar;8(3):892-900. doi: 10.1016/j.jaip.2019.10.003. Epub 2019 Oct 23.
5
Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor.C1酯酶抑制剂正常的遗传性血管性水肿患者的临床特征及治疗结果
World Allergy Organ J. 2022 Jan 27;15(1):100621. doi: 10.1016/j.waojou.2021.100621. eCollection 2022 Jan.
6
The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency.认识和管理一种罕见的血管性水肿的重要性：C1 抑制剂缺乏引起的遗传性血管性水肿。
Postgrad Med. 2021 Aug;133(6):639-650. doi: 10.1080/00325481.2021.1905364. Epub 2021 Jul 6.
7
Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.美国遗传性血管性水肿预防性治疗的现有选择：基于患者的考虑因素。
Allergy Asthma Proc. 2012 May-Jun;33(3):235-40. doi: 10.2500/aap.2012.33.3573.
8
Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema.康耐思他（重组人 C1 酯酶抑制剂）用于预防遗传性血管性水肿成年和青少年患者的发作。
Expert Rev Clin Immunol. 2018 Sep;14(9):707-718. doi: 10.1080/1744666X.2018.1503055. Epub 2018 Sep 13.
9
[Guidelines for the diagnosis and treatment of hereditary angioedema].[遗传性血管性水肿诊断和治疗指南]
Lijec Vjesn. 2014 May-Jun;136(5-6):117-29.
10
A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.红斑性结节性天疱疮期间 C1 抑制剂浓缩物在遗传性血管性水肿中的新预防作用。
Immunol Lett. 2017 Sep;189:90-93. doi: 10.1016/j.imlet.2017.05.015. Epub 2017 May 31.
引用本文的文献
1
Managing Hereditary Angioedema in a Three-Generation Family: Danazol's Promise in Resource-Limited Settings.三代家族遗传性血管性水肿的管理：达那唑在资源有限环境中的前景
Cureus. 2024 Nov 26;16(11):e74481. doi: 10.7759/cureus.74481. eCollection 2024 Nov.
2
Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series.雄激素转换和遗传性血管性水肿长期预防的现实管理：单中心病例系列。
Orphanet J Rare Dis. 2024 Jul 9;19(1):257. doi: 10.1186/s13023-024-03251-5.
3
Sensitivity to change and minimal clinically important difference of the angioedema control test.血管性水肿控制试验对变化的敏感性及最小临床重要差异
Clin Transl Allergy. 2023 Sep;13(9):e12295. doi: 10.1002/clt2.12295.
本文引用的文献
1
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update.《遗传性血管性水肿管理的国际 WAO/EAACI 指南-2021 年修订版》。
Allergy. 2022 Jul;77(7):1961-1990. doi: 10.1111/all.15214. Epub 2022 Feb 3.
2
What's New in the Treatment of Urticaria and Angioedema.荨麻疹和血管性水肿治疗的新进展。
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2170-2184. doi: 10.1016/j.jaip.2021.03.012.
3
Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey.遗传性血管性水肿患者的临床特征和疾病负担：一项多国患者调查的结果。
Orphanet J Rare Dis. 2021 Feb 18;16(1):94. doi: 10.1186/s13023-021-01717-4.
4
Current and Prospective Targets of Pharmacologic Treatment of Hereditary Angioedema Types 1 and 2.遗传性血管性水肿 1 型和 2 型的药物治疗的当前和潜在靶点。
Clin Rev Allergy Immunol. 2021 Aug;61(1):66-76. doi: 10.1007/s12016-021-08832-x. Epub 2021 Jan 9.
5
Hereditary angioedema: On-demand treatment of angioedema attacks.遗传性血管性水肿：按需治疗血管性水肿发作。
Allergy Asthma Proc. 2020 Nov 1;41(Suppl 1):S26-S29. doi: 10.2500/aap.2020.41.200066.
6
Validation of the Angioedema Control Test (AECT)-A Patient-Reported Outcome Instrument for Assessing Angioedema Control.血管性水肿控制测试（AECT）的验证——一种用于评估血管性水肿控制情况的患者报告结局工具。
J Allergy Clin Immunol Pract. 2020 Jun;8(6):2050-2057.e4. doi: 10.1016/j.jaip.2020.02.038. Epub 2020 Mar 12.
7
Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe.遗传性血管性水肿的社会经济负担：欧洲遗传性血管性水肿疾病负担研究结果
Orphanet J Rare Dis. 2014 Jul 4;9:99. doi: 10.1186/1750-1172-9-99.
8
The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe.遗传性血管性水肿的人文负担：欧洲疾病负担研究的结果
Allergy Asthma Proc. 2014 Jan-Feb;35(1):47-53. doi: 10.2500/aap.2013.34.3685. Epub 2013 Nov 22.
9
Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients.遗传性和获得性C1抑制剂缺乏症：235例患者的生物学和临床特征
Medicine (Baltimore). 1992 Jul;71(4):206-15. doi: 10.1097/00005792-199207000-00003.
Zotero 插件